The survival rate after 30 days of treatment was approximately 85% for anti-RhoC siRNA-treated group, indicating that lipofectamine mediated anti RhoC siRNA had a significant effect on tumor growth reduction as well as survival rate enhancement. Here, RHOC is linked to neoplasm.